Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype
- PMID: 24925503
- DOI: 10.1007/s11102-014-0578-5
Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype
Abstract
Purpose: The subtypes of somatotroph-cell pituitary adenomas have been correlated with clinical and histopathological variables. Densely granulated somatotroph-cell (DG) adenomas are typically highly responsive to somatostatin analog drugs, whereas sparsely granulated somatotroph-cell (SG) are less responsive. The aim of the study is to determine the effect of stereotactic radiosurgery (SRS) on remission and development of new pituitary deficiency according to the different subtypes of growth hormone (GH) secreting adenomas.
Methods: A total of 176 patients underwent SRS for acromegaly at the University of Virginia. Diagnosis of acromegaly was based on the combination of clinical features and biochemical assessment including the serum GH level, and age- and gender-matched serum insulin-like growth factor-1 level. All patients underwent endocrine and neuro-imaging evaluations before and after SRS. Histological specimens were available in 73 patients.
Results: The histopathological examination showed 34 patients had a DG adenoma, 19 had a SG adenoma, eight had a mixed DG/SG pattern, while other rare mixed subtypes were present in 12 patients. Patients who had a SG adenoma were more likely to be younger and female, and the SG adenomas appeared to be more invasive into the cavernous sinus. With a median follow-up of 67 months (range 6-188 months), 55/73 patients (75.3%) achieved remission. The median time to remission was 26 months (range 6-102 months). The actuarial remission rates in the DG adenoma group at 2, 4, and 6 years post-radiosurgery were 35.1, 71.4, and 79.3%, respectively, while those in SG adenoma group were 35.4, 73.1, and 82.1%, respectively.
Conclusion: While patients who had a SG adenoma may be less responsive to medical therapy, they exhibited similar responses to SRS as patients with a DG adenoma. For SG adenomas, which respond less well to medical therapy, earlier SRS may be reasonable for consideration.
Similar articles
-
Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases.J Clin Endocrinol Metab. 2024 Nov 18;109(12):e2178-e2187. doi: 10.1210/clinem/dgae126. J Clin Endocrinol Metab. 2024. PMID: 38436926
-
Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.Neurosurg Focus. 2020 Jun;48(6):E10. doi: 10.3171/2020.3.FOCUS2080. Neurosurg Focus. 2020. PMID: 32480366
-
Stereotactic radiosurgery for acromegaly.J Clin Endocrinol Metab. 2014 Apr;99(4):1273-81. doi: 10.1210/jc.2013-3743. Epub 2014 Jan 28. J Clin Endocrinol Metab. 2014. PMID: 24471574
-
Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.Pituitary. 2006;9(3):221-9. doi: 10.1007/s11102-006-0267-0. Pituitary. 2006. PMID: 17036195 Review.
-
Acromegaly.Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4. Pituitary. 2006. PMID: 17077948 Review.
Cited by
-
Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.Endocrine. 2019 Nov;66(2):310-318. doi: 10.1007/s12020-019-02029-1. Epub 2019 Jul 31. Endocrine. 2019. PMID: 31368083
-
Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis.Pituitary. 2023 Dec;26(6):653-659. doi: 10.1007/s11102-023-01353-0. Epub 2023 Sep 21. Pituitary. 2023. PMID: 37735314 Review.
-
Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway.Neuropathol Appl Neurobiol. 2021 Apr;47(3):415-427. doi: 10.1111/nan.12675. Epub 2020 Dec 20. Neuropathol Appl Neurobiol. 2021. PMID: 33128255 Free PMC article.
-
Empirical versus progression-guided stereotactic radiosurgery for non-functional pituitary macroadenomas after subtotal resection.J Neurooncol. 2019 Apr;142(2):291-297. doi: 10.1007/s11060-019-03095-1. Epub 2019 Jan 12. J Neurooncol. 2019. PMID: 30635763
-
Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.Pituitary. 2018 Feb;21(1):1-9. doi: 10.1007/s11102-017-0836-4. Pituitary. 2018. PMID: 28849339
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources